Sponsored Symposia
Navigating changes in NF1-PN care: Expert insights from clinical practice
Date: Monday, 29 June 2026
Time: 7:00 AM - 7:45 AM
Location: Cockle Bay Room 1
Alexion, AstraZeneca Rare Disease-sponsored symposium at the 2026 ISPNO Conference. Featuring talks from:
Professor Michael Fisher, Children's Hospital of Philadelphia, PA, USA
Dr Sue-Faye Siow, Royal North Shore Hospital, St Leonards, NSW, Australia
Objectives:
Provide expert clinical insights into the use of selumetinib in patients with NF1-PN across their lifespan, including considerations for long-term disease management
Discuss how NF1-PN management and patient treatment goals may evolve as a patient ages
Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care
Date: Monday, 29 June 2026
Time: 12:30-12:45 PM: Check-In & Lunch 12:45-1:25 PM: In-Person & Virtual Symposium
Location: Cockle Bay Room 2
Neurofibromatosis type 1 (NF1) is a complex genetic disorder characterized by the growth of tumors along nerves, most commonly plexiform neurofibromas (PNs), which can cause significant pain, disfigurement, and functional impairment. Historically, management of NF1-PNs relied on supportive care and surgical intervention, which offered little reprieve from debilitating symptoms. Newer targeted therapies such as MEK inhibitors (MEKi) have proven capable of slowing or shrinking PNs and alleviating symptoms, fundamentally transforming the natural history of NF1-PNs across the globe.
Join PeerView at the 2026 ISPNO Meeting to hear real-world insights on the evidence with MEKi therapy, gain global perspectives on developing personalized treatment plans, and learn best practices for navigating specialist referrals, long-term monitoring, toxicity management, and transitioning patients to adult care. This dynamic educational event offers a unique opportunity to engage with peers and discover how clinicians around the world are advancing care for patients with NF1-PNs. Register now!
Jim Whittle, MBBS, PhD, FRACP, will be joined by Laura “Katie” Metrock, MD, as presenters for this educational activity.
This CME/AAPA activity is provided by PVI, PeerView Institute for Medical Education.
This activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.
Cure Fund Session
Date: Monday, 29 June 2026
Time: 12:40 PM - 1:10 PM
Location: Cockle Bay Room 1
The Cure Fund provides up to $50,000 USD in targeted, early-stage funding to support high-potential, innovative research concepts, the kind of bold “2 am Big Ideas” that keep you awake and may require early, proof-of-concept funding. Applications must be focused on paediatric brain tumour research, with preference given to projects that embrace universal-cure strategy implications.
Turning Pain Into Action
Date: Tuesday, 30 June 2026
Time: 7:00 AM - 7:45 AM
Location: Cockle Bay Room 1
The Medulloblastoma Initiative (MBI) is a global effort dedicated to accelerating the development of effective treatments—and ultimately a cure—for medulloblastoma, the most common malignant brain tumor in children. Founded by Fernando Goldsztein alongside Dr. Roger Packer, MBI brings together leading scientists and institutions in a highly coordinated, collaborative model designed to fast-track research and move discoveries more quickly into clinical trials.
Recognized by MIT for its innovative approach, MBI aligns funding, data sharing, and scientific priorities to shorten the path from laboratory breakthroughs to patient impact. Donations are managed by Children’s National Hospital in Washington, D.C., ensuring strong governance and direct support for cutting-edge science.
Key speaker: Fernando Goldsztein.
Fernando Goldsztein is a Brazilian businessman and the founder of The Medulloblastoma Initiative (MBI). Driven by a deeply personal journey—his son’s diagnosis—he has transformed pain into action, dedicating himself to accelerating progress in pediatric oncology.
Rethinking Gliomatosis Cerebri (GC) in Children and Young Adults
Date: Tuesday, 30 June 2026
Time: 7:00 AM - 7:45 AM
Location: Cockle Bay Room 2
Rethinking Gliomatosis Cerebri (GC) in Children and Young Adults
Chairs:
Chris Jones (London)
David Castel (Paris)
Speakers:
Kshitij Mankad (London)
Matthew Clarke (London)
Andres Morales La Madrid (Barcelona)
Children’s Brain Tumor Network (CBTN): Advancing Community-Led Discovery
Date: Tuesday, 30 June 2026
Time: 12:10 PM - 12:55 PM
Location: Cockle Bay Room 2
Progress in pediatric neuro-oncology increasingly depends on the ability to connect data, expertise, and investigators across institutions and borders. The Children’s Brain Tumor Network (CBTN) has enabled a growing global community to contribute to and learn from shared datasets spanning molecular, clinical, and imaging domains.
This session will bring together investigators leveraging these resources to explore tumor biology, characterize disease trajectories, and identify new opportunities for therapeutic intervention. Through a series of case studies and emerging findings, speakers will highlight how collaborative, data-driven approaches are shaping current research and informing future directions in pediatric neuro-oncology.
“Targeting the Change” – From Diagnosis to Therapy in H3 K27M Diffuse Gliomas
This session, led by three experts, will encompass key advances in the understanding and management of H3 K27M diffuse gliomas. The talks will cover evolving disease biology, including tumor–neuron interactions, as well as emerging clinical strategies and therapeutic approaches.The session will also provide an overview of emerging clinical approaches, including investigational therapies such as ONC201 (dordaviprone), and discuss ongoing efforts to address the significant unmet need in this patient population.
Lectures
Evolution of Management Strategies for Pediatric H3 K27M-mutant Diffuse Gliomas
Michelle Monje (Stanford University)
ONC201 in H3 K27M–mutant Diffuse Gliomas: Clinical Development with Emerging Evidence
Cassie Kline (Children’s Hospital of Philadelphia)
Date: Tuesday, 30 June 2026
Time: 12:10 PM - 12:55 PM
Location: Cockle Bay Room 1
